Most Biomarkers Supporting Drug Approvals Lack Strong Supporting Data, Study Says

Almost 60 percent of surrogate markers supporting FDA approvals for nononcologic drugs for chronic diseases aren’t backed up by meta-analyses showing a strong association between the marker and relevant clinical endpoints, a new JAMA Network study says.
Source: Drug Industry Daily